What Has Been the Growth Trajectory for the Actinic Keratosis Treatment Market in Recent Years?
The actinic keratosis treatment market has seen considerable growth due to a variety of factors.
• The market for the treatment of actinic keratosis has experienced significant growth in the past few years. Projected growth is from $3.2 billion in 2024 to $3.44 billion in 2025, with a compound annual growth rate (CAGR) of 7.6%. Factors contributing to past growth include adherence to treatment, competitive market conditions, initiatives to educate patients, practices in dermatology, and the execution of research and clinical trials.
How Does the Forecast Look for the Actinic Keratosis Treatment Market?
The Actinic Keratosis Treatment market is expected to maintain its strong growth trajectory in upcoming years.
• Predictions indicate a substantial increase in the market size for treatment of actinic keratosis in the coming years. It is projected to expand to $4.69 billion in 2029, growing at a compounded annual growth rate (CAGR) of 8.0%.
Factors such as patient education and engagement, the integration of digital health, rising consciousness, preventive dermatology efforts, and trends in personalized medicine are contributing to this growth during the projected period. The market will also be shaped by key trends such as a shift towards combination therapies, advancements in technology, personalized treatment strategies, escalating incidence rates, and the use of minimally invasive procedures.
What Are The Leading Drivers Of Growth In The Actinic Keratosis Treatment Market?
The continual increase in the occurrence of actinic keratosis is predicted to drive the expansion of the actinic keratosis treatment market. Actinic keratosis, defined as a rough, scaly patch of skin resulting from years of sun exposure, can be recognized and suppressed precancerous lesions by treatment, lowering the risk. An escalation in cases of actinic keratosis necessitates a heightened demand for actinic keratosis treatment products, potential drugs under study, and prescribed use of topical remedies. For example, World Cancer Research Fund International, a UK-based institution, reported in an article in February 2022, that the number of fresh actinic keratosis cases in 2020 surpassed 150,000 and jumped to 197,700 in 2022. Hence, the escalating occurrence of actinic keratosis propels the growth of the actinic keratosis treatment market.
How Are The Segments Defined Within The Global Actinic Keratosis Treatment Market?
The actinic keratosis treatment market covered in this report is segmented –
1) By Treatment: Topical Treatment, Procedural Modality, Photodynamic Therapy, Other Treatments
2) By Medication: Fluorouracil Cream, Imiquimod Cream, Ingenol Mebutate Gel, Diclofenac Gel
3) By End User: Hospitals, Private Dermatology Clinics, Laser Therapy Centers, Cancer Treatment Centers, Spas And Rejuvenation Centers, Homecare
Subsegments:
1) By Topical Treatment: 5-Fluorouracil (5-FU), Imiquimod, Ingenol Mebutate, Diclofenac
2) By Procedural Modality: Cryotherapy, Curettage And Electrosurgery, Laser Therapy, Chemical Peels
3) By Photodynamic Therapy: ALA-Based PDT, MAL-Based PDT
4) By Other Treatments: Immunotherapy, Phototherapy, Combination Therapies
Pre-Book The Actinic Keratosis Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Actinic Keratosis Treatment Market?
Top players in the actinic keratosis treatment market are prioritizing the development of novel products such as prescription drugs to bolster treatment effectiveness, elevate patient results, and broaden their product array. Prescription drugs require a healthcare professional's written consent, specifying the medication's name, dosage, and usage duration. These drugs, used for particular medical conditions, necessitate meticulous supervision due to potential side effects. For instance, in December 2022, Biofrontera AG, a pharmaceutical firm based in Germany, unveiled Ameluz., a topical gel with 5-aminolevulinic acid. This gel is employed alongside photodynamic therapy (PDT) to manage mild to moderate actinic keratoses (AK) and specific basal cell carcinoma types. The treatment procedure involves applying the gel onto the skin areas affected, then illuminating them with a BF-RhodoLED lamp, thereby activating the medication.
Who Are the Key Players In The Actinic Keratosis Treatment Market?
Major companies operating in the actinic keratosis treatment market include:
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• Hill Dermaceuticals Inc.
• Bausch Health Companies Inc.
• LEO Pharma A/S
• Almirall SA
• Biofrontera AG
• Galderma SA
• Mylan NV
• Cipher Pharmaceuticals Inc.
• Pierre Fabre Pharmaceuticals Inc.
• Tolmar Pharmaceuticals Inc.
• Stanford Chemicals Company
• Glaxo Smith Kline PLC
• Alma Lasers Ltd.
• 3M Company
• Nestle SA
• Cutanea Life Sciences Inc.
• DUSA Pharmaceuticals Inc.
• Foamix Pharmaceuticals Ltd.
• G&W Laboratories Inc.
• Hikma Pharmaceuticals PLC
• Innocutis Holdings LLC
• Mayne Pharma Group Limited
• Meda AB
• Merz Pharma GmbH & Co KGaA
• Perrigo Company PLC
• PharmaDerm A division of Fougera Pharmaceuticals Inc.
• Promius Pharma LLC
• Ranbaxy Laboratories Limited
• Sandoz International GmbH
• Stiefel Laboratories Inc.
• Teva Pharmaceutical Industries Ltd.
• Valeant Pharmaceuticals International Inc.
• Zydus Pharmaceuticals Inc.
• Dermira Inc.
• Menlo Therapeutics Inc.
• Sol-Gel Technologies Ltd.
• Verrica Pharmaceuticals Inc.
What Is The Most Dominant Region In The Actinic Keratosis Treatment Market?
North America was the largest region in the actinic keratosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
